- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00539526
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
April 10, 2019 updated by: Allergan
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of open-angle glaucoma (pseudoexfoliative or pigmentary glaucomas are allowed) or ocular hypertension
Exclusion Criteria:
- Known contraindication to latanoprost, bimatoprost or travoprost
- Uncontrolled systemic disease
- Active ocular disease other than glaucoma or ocular hypertension
- Pregnant or lactating women or women of childbearing potential NOT utilizing a medically acceptable form of birth control
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
bimatoprost 0.03%
|
bimatoprost 0.03%, 1 drop nightly for 3 months
Other Names:
|
Active Comparator: 2
travoprost 0.004%
|
travoprost 0.004% eye drops, 1 drop nightly for 3 months
Other Names:
|
Active Comparator: 3
latanoprost 0.005%
|
latanoprost 0.005%, 1 drop nightly for 3 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3
Time Frame: Baseline, Month 3
|
Change from baseline in mean conjunctival hyperemia scores at month 3. Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye).
Hyperemia was graded using a 5-point scale in which 0=no redness and +3=deep, diffuse redness.
A negative number change from baseline indicates improvement.
|
Baseline, Month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Corneal Staining With Fluorescein at Month 3
Time Frame: Baseline, Month 3
|
Change from baseline in corneal staining with fluorescein at month 3.
The cornea is the transparent front part of the eye which covers the iris and pupil.
To detect the presence or absence of corneal puncta (tiny disruptions in the surface of the eye), fluorescein dye is administered into the eye and the eye is graded using a 5-point scale where 0 equals no puncta (best), and 3 equals too many puncta to count (worst).
A negative number change from baseline indicates improvement.
|
Baseline, Month 3
|
Change From Baseline in Tear Break-Up Time (TBUT) at Month 3
Time Frame: Baseline, Month 3
|
Change from baseline in TBUT at month 3. TBUT is defined as the time (seconds) required for dry spots to appear on the surface of the eye after blinking.
The longer it takes, the more stable the tear film.
A positive number change from baseline indicates improvement.
|
Baseline, Month 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
September 1, 2008
Study Registration Dates
First Submitted
October 2, 2007
First Submitted That Met QC Criteria
October 3, 2007
First Posted (Estimate)
October 4, 2007
Study Record Updates
Last Update Posted (Actual)
April 24, 2019
Last Update Submitted That Met QC Criteria
April 10, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MA-LUM-07-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on Bimatoprost 0.03%
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedIdiopathic Eyelash HypotrichosisRussian Federation, Sweden, United States, United Kingdom
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleChina
-
AllerganCompletedEyelash HypotrichosisUnited States
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleChina
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedEyelash HypotrichosisKorea, Republic of
-
Indiana University School of MedicineCompleted
-
Innovative MedicalCompleted
-
AllerganCompletedEyelash HypotrichosisJapan